Xcout Intel
Endeavor Biomedicines, Inc.
Endeavor BioMedicines, Inc. is a San Diego-based biotechnology company focused on developing novel treatments for conditions such as fibrosis.
Subscribe to see Endeavor Biomedicines, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Endeavor Biomedicines, Inc. at a glance
Endeavor Biomedicines, Inc. is a biotechnology company headquartered in United States. It has raised at least $233.6M across the 2 funding rounds on record. Its most recent funding round, Series C, raised $132.6M in April 2024. Xcout tracks 13 named people at Endeavor Biomedicines, Inc., including Enoch Kariuki (President).
Endeavor Biomedicines, Inc. leadership
- Enoch KariukiPresident
- Chris KruegerChief Operating Officer
- Vishaal TurakhiaChief Financial Officer
- Lisa Lancaster, MDChief Medical Officer
- John HoodCo-Founder & Chief Executive Officer
- Miguel de los RiosCo-Founder & Chief Scientific Officer
7 more named people on record for Endeavor Biomedicines, Inc., with roles, board committees and tenure — see the full roster →
Endeavor Biomedicines, Inc. funding rounds
At least $233.6M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $132.6M | 13 named | |
| Series C | $101M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Endeavor Biomedicines, Inc. competitors
A few of Endeavor Biomedicines, Inc.'s closest competitors — see the full list of competitors and alternatives →
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company located in Mission Viejo, California, focused on developing a platform of compounds for biodefense and fibrosis applications.
MDI Therapeutics, Inc. is a pharmaceutical company headquartered in Novi, Michigan. The company specializes in researching and developing novel therapeutics for the treatment of fibrosis and related fibrotic diseases.
4F Biotech is a biotechnology firm focused on developing innovative therapeutic approaches, screening platforms, and diagnostic tools to combat fibrosis and inflammatory processes.
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Endurance Biotech, Inc. is a biopharmaceutical company that develops first-in-class oral small molecules designed to restore mitochondrial and lysosomal function for the treatment of neurodegenerative, metabolic, and age-related diseases. Its lead clinical program, T-168, targets Parkinson's disease by addressing interconnected cellular systems, reducing neuroinflammation, and enhancing autophagy.
Get Endeavor Biomedicines, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Endeavor Biomedicines, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access